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The first recorded evidence of the presence of circulating tumor cells (CTCs) in the peripheral blood of cancer patients 
was documented in 1869. In the past few decades, experiments have shown that cancer-related alterations can be 
detected at the DNA and RNA levels. Both DNA and mRNA molecular markers can be used for the detection of CTCs in 
patients with various malignancies. Currently, modern molecular biological and cell sorting techniques make their detec-
tion and characterization more practicable. These recent advances in our understanding should lead to the development 
of new molecular markers for predicting micrometastasis, as well as the identification of new targets for anti-metastatic 
therapies. This article reviews recent advances in molecular and clinical aspects of CTCs, especially by DNA and mRNA 
markers, for an early detection of colorectal cancer and other conditions.
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Introduction
Colorectal cancer (CRC) is a significant pubic health 
problem; there are nearly one million new cases of 
colorectal cancer diagnosed worldwide each year and 
half a million deaths.1 In Western countries, CRC is 
the secondary leading cause of cancer-related 
death, and is the third leading cause of cancer-
related death in Taiwan. In Taiwan, it is estimated 
that over 10,000 CRC patients are diagnosed each 
year—over 4100 patients died of this disease in 2007.2 
In Taiwan, the incidence of CRC is rising, and grad-
ually approaching western levels. The prognosis of 
CRC patients is dependent on a number of key 
factors: pathological, clinical and biological. Like 
other solid tumors, CRC is staged pathologically on 
the basis of the extent of primary tumor invasion and 
the metastatic spread to lymph nodes or to distant 
organs. Although 5-year survival rates for CRC have 
significantly increased, from around 50% to more than 
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65% in the USA within the last three decades,3 
30−40% of International Union Against Cancer (UICC) 
stage II−III patients undergoing curative intent (R0) 
resection will eventually experience relapse and die 
of the disease.4−8 While the death rate of CRC is 
declining in the West, it is increasing in Asian coun-
tries.9 The fact that the overall survival rate re-
mains poor strongly suggests that the dissemination 
of these cells occurs early in the disease process. 
This emphasizes the need for finding feasible diag-
nostic methods with sufficient sensitivity and spe-
cificity earlier.
This review focused on the results of recent 
basic and clinical research on the circulating tumor 
cells (CTCs) in CRC patients taking potential diag-
nostics, prognostics, and applications into consid-
eration, especially the molecular detection of CTCs 
in peripheral blood.
Background of Micrometastasis and CTCs
Undetected micrometastases can contribute to the 
failure of primary treatment. Therefore, the identi-
fication of occult metastases in patients with early 
stage cancer could have a substantial clinical impact 
on the prognosis and optimal therapy for patients 
with CRC. Models of metastasis indicate that pri-
mary tumor cells spread to other organs via circu-
lation (blood and lymphatics). Hematogenous and 
lymphatic spread are the most common metastases 
associated with CRC, and these are the most impor-
tant factors associated with prognosis and outcome. 
In the process of metastasis, tumor cells shed from 
the primary tumor, spread through the blood stream 
or lymphatic system, bind to the relevant endothe-
lium, and spread into the extracellular space. At all 
times the cells escape the host’s defense mecha-
nisms, finally to form a new metastatic lesion, the 
most life-threatening component of cancer.10,11
Since early detection is an important factor in 
reducing cancer mortality, the development of a sen-
sitive, specific, and convenient diagnostic method 
for detecting CRC at a very early stage is an issue of 
utmost importance, especially for CRC patients after 
curative resection. Sensitive detection of occult car-
cinoma cells in the peripheral blood of CRC patients 
has important prognostic and therapeutic implica-
tions. Exploratory metastases research has gradually 
accumulated since the 1960s, with the development 
of animal models and cell culture techniques.
CTC Detection Methods
Identification and characterization of CTCs requires 
extremely sensitive and specific analytical methods, 
such as immunocytochemical or molecular tools, 
which are usually combined with prior enrichment 
procedures, including density gradient centrifuga-
tion, immunomagnetic procedures, or filtration. The 
importance of CTC emboli in the spread of metas-
tases has been shown.12,13 Since the early 1980s, 
when monoclonal antibodies (mAbs) became rou-
tinely available, followed by the application of 
molecular detection, new specific and sensitive 
methods were used.14,15 However, such neoplastic 
cells may be present in the bloodstream in very 
low numbers and may not be detected by conven-
tional methods. These detection techniques were 
later combined with specific cell enrichment tech-
niques, such as magnetic16,17 and flow cytometric cell 
separation.18
Immunocytochemical techniques
In one type of immunocytochemical technique, mAbs 
against various epithelial specific antigens are used 
to detect, and often enumerate, the tumor cells. 
These techniques are robust and have been dem-
onstrated to work in an in vitro model system. The 
mAbs label the tumor cells that can be subse-
quently visualized directly or indirectly by fluores-
cent dyes or colorimetrically.17−19 A diverse repertoire 
of antigens has been investigated; by far the most 
common accepted markers for CTCs are the intrac-
ellular cytokeratins (CK).17−20 The detection limit for 
cytometric methodology is one specific tumor cell 
among 106 in the background of millions of normal 
cells when one or more different monoclonal anti-
bodies against cytokeratins have been used.18,21 
Besides automated devices for rapid microscopic 
screening,22,23 the FDA-approved CellSearch™ sys-
tem has gained considerable attention because it 
allows automated enrichment and CK staining of CTC 
and their distinction from leukocytes in peripheral 
blood.24,25 However, there are two main disadvan-
tages of using immunocytochemical techniques: 1) 
the sensitivity to detect micrometastasis by these 
techniques has been questioned because of the 
limited amount of screened cells; and 2) there is a 
lack of methodological standardization.
Recently, a new immunological technique termed 
EPISPOT (EPithelial ImmunoSPOT) was introduced for 
CTC analyses.25 This technique detects secreted or 
actively released specific marker proteins by via-
ble CTCs using an adaptation of the enzyme-linked 
immunospot technology.26 Together, these problems 
are thought to be the reason for many discrepan-
cies in the immunocytochemical data from dif-
ferent studies,27,28 with reported false-positive 
rates ranging from < 1% to > 80%. Recently, Nagrath 
et al presented a microfluid platform called the 
“CTC-chip”. It consists of an array of anti-EpCAM 
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antibody-coated microposts capable of capturing 
CTCs under precisely controlled laminar flow con-
ditions in whole blood.29 It has gained considerable 
attention in the research community.
Nucleic acid-based methodology
Genetic and epigenetic alterations of multiple 
cancer-related genes and molecules have been 
implicated in the development and progression 
of human CRC.30−32 These are thought to drive the 
transition from normal epithelium through increas-
ing adenomatous dysplasia to CRC. Genetic alter-
ations in tumor cells can be detected at the level 
of DNA, RNA, or protein. It is not always certain that 
a change in DNA (genotype) or messenger ribonu-
cleic acid (mRNA) expression will be successfully 
translated to protein (phenotype). At the DNA level, 
the detection of oncogenes/tumor suppressor gene 
mutations, microsatellite alterations, chromosomal 
translocations, and hypermethylation of promoter 
sequences has been demonstrated. At the RNA level, 
the overexpression of tumor-associated genes has 
been shown.
In 1977, Leon et al reported that cancer patients 
have higher plasma levels of circulating DNA com-
pared with healthy controls.33 Moreover, greater 
amounts of DNA were found in the plasma or serum 
of patients with metastases compared with those 
with localized disease. The same study showed that 
plasma DNA from cancer patients was of tumoral 
origin (since it shared some biophysical properties 
common to DNA of cancer cells).34 It was later 
demonstrated that tumor-related DNA was not con-
fined to any specific cancer type, but appeared to 
be a common finding across different malignan-
cies.35 Both intact tumor cells and cell-free nucleic 
acids (from cancer cells) circulate in the blood of 
cancer patients. The precise mechanism of the 
release of circulating DNA into the bloodstream re-
mains to be proven; however, cell-free DNA is 
thought to be released into the blood by apoptotic 
and necrotic cells by the primary tumor early during 
tumorigene sis.36 Measurements of cell-free DNA 
have previously been shown to have diagnostic po-
tential in a number of malignant diseases and also 
to be a noninvasive approach for early detection of 
carcinoma.37 Furthermore, it has been suggested 
that living cells may actively release their DNA into 
the blood.35 Consequently, detection of circulating 
DNA in the peripheral blood of CRC patients is 
a new research area—plasma/serum may eventually 
be a suitable source for the development of noninva-
sive diagnostic, prognostic, and follow-up tests for 
cancer. The major disadvantage of circulating DNA 
material is that it can be released by dying tumor 
cells and remains in the circulation because of its 
relatively high stability in comparison to RNA. There-
fore, the presence of DNA markers does not neces-
sarily indicate the presence of viable CTCs, but is 
indicative of a tumor burden.38
The same method used to detect DNA in CTCs can 
be applied to investigate free RNA in the plasma of 
cancer patients. Although it has been proposed that 
RNA is less stable than DNA (because of its supposed 
susceptibility to degradation by blood RNases), ex-
tracellular RNA exists with sufficient integrity as 
to allow reverse transcription-PCR (RT-PCR) ampli-
fication. This represents a new tool in the strategy 
to identify nucleic acids (cDNA) in the plasma of 
cancer patients and determine their value as prog-
nostic factors. Studies with mRNA markers are par-
ticularly promising due to their close association 
with malignancy. One study showed that 92% of CRC 
patients showing circulating epithelial tumor cells 
displayed the same positive RNA markers in plas-
ma.39 Recently, work on mRNA, using similar meth-
odology, has shown promising results—the percentage 
of tumors (different malignancies) detectable with 
this assay appears to be higher than that found with 
DNA markers.40
The most commonly used technique for the detec-
tion of nucleic acid material of CTCs are the PCR-
based methods, including PCR, RT-PCR, or real-time 
quantitative-CR (Q-PCR) assays. These now permit 
sensitive detection of CTCs in peripheral blood. 
The introduction of PCR-based technology in the late 
1980s and refinements over the past 10 years have 
allowed us to detect and quantify extremely small 
quantities of nucleic acid. The first drawback of PCR-
based methods is that the tumor cells of interest 
cannot be morphologically identified and isolated 
for further analyses. Another disadvantage is that 
they are potentially oversensitive—they can detect 
minimal amounts of mRNA expression in a non tissue-
specific manner (illegitimate transcription), meaning 
that they are usually highly sensitive but insufficiently 
specific.41,42 There is currently good evidence that 
RT-PCR or Q-PCR enables the detection of minute 
quantities of a tumor-related molecular marker in 
the peripheral blood. Although these methods pro-
vide valuable information, one of the major limita-
tions is that neither RT-PCR nor Q-PCR is able to 
analyze more than one molecular marker in a single 
experiment. Several recent RNA-based approaches 
focus only on the clinical significance of single marker 
analysis. Due to heterogeneity of the expression of 
tumor-related genes, a multi-marker assay is thought 
to be more reliable and sensitive than a single marker 
assay. Consequently, a group of candidate genes 
re lated to CRC carcinogenesis would likely overcome 
inter-tumoral variations, and increase the detection 
rate for CTCs.18 Applying RT-PCR or Q-PCR for mul-
tiple gene expression would be a time-wasting and 
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laborious task in clinical practice. Therefore, the de-
velopment of a robust assay for detecting CTCs with 
an excellent high-sensitivity and high-throughput 
quality by a panel of informative molecular markers 
simultaneously is imperative. Recently, our laboratory 
developed a colorimetric membrane-array method 
for the detection of CTCs in the peripheral blood 
of patients with various malignancies.43−47 It dem-
onstrated a detection sensitivity of more than five 
cancer cells per 1 mL of blood (around one cancer 
cell/106 leukocytes), with a sensitivity and speci-
ficity of detection of CTCs of around 82−92%. Com-
pared with other published blood-based RT-PCR 
or Q-PCR assays—their sensitivity reported to be 
between 34% and 88%48−51—this membrane-array 
assay was more accurate in discriminating CRC 
patients from healthy subjects. Moreover, a highly 
significant correlation was found between our de-
signed membrane-arrays and Q-PCR assay (p < 0.001, 
r = 0.979).45
Clinical Significance of Circulating 
Tumor Cells by Molecular Detection
DNA markers
APC and K-ras mutations are considered as early-
stage developments of CRC, whereas p53 mutations 
are thought to be relatively late events in the tu-
morigenesis of CRC.30,31 K-ras mutations—found in 
circulating DNA extracted from serum samples of 
patients with CRC—show that there is a correspon-
dence between serum and tissue K-ras patterns.52 
Previously, we conducted a comprehensive study to 
analyze APC, K-ras, and p53 gene mutations in pri-
mary tumor tissues and their paired preoperative 
serum samples in 118 CRC patients.32 The detec-
tion rates of the three serum molecular markers in 
patients harboring APC, K-ras, and p53 gene muta-
tions were 34.6% (18/52), 38.9% (21/54), and 37.2% 
(16/43), respectively. This finding is consistent with 
the results published by Hibi et al,53 who showed 
that either a K-ras or p53 mutation was detected in 
40% of the CRC patients’ serum. Of these patients—
those whose tumors had at least one of these three 
gene mutations—45.1% (41/91) were identified as 
positive for the corresponding serum molecular 
marker(s). We found that both preoperative serum 
APC and p53 molecular markers were closely cor-
related with lymph node metastasis and UICC stage 
(both p < 0.05). Moreover, the serum overall molec-
ular markers (at least one of the three markers) were 
prominently associated with depth of tumor inva-
sion (p = 0.033), lymph node metastasis (p < 0.001), 
and UICC stage (p < 0.001). In addition, a significantly 
higher postoperative metastasis/recurrence rate was 
found in patients positive for overall molecular 
markers compared with those who were negative 
(p < 0.001). APC and K-ras molecular markers were 
more frequently observed in patients with locore-
gional metastasis (both p < 0.05), while the p53 mo-
lecular marker was usually detected in cases with 
peritoneal metastasis (p = 0.004).
Likewise, our previous investigation proved that 
mutant DNA was not detected in the serum speci-
mens of 26 patients whose tumors tested negative 
for genetic alterations, or in healthy subjects.54 
With regard to tumor stage, we observed the ten-
dency toward a stage-dependent difference in the 
occurrence of APC, K-ras, and p53 mutations in the 
serum samples of CRC patients. Overall, the presence 
of at least one marker alteration was observed in 
0% (0/7) in Dukes’ A, 22.4% (11/49) in Dukes’ B, 48.7% 
(19/39) in Dukes’ C, and 66.7% (6/9) in Dukes’ D 
classifications. Finally, APC, K-ras and p53 gene 
mutations seem to be applicable genetic markers 
for the detection of CTC-related genes from CRC 
patients. Consistent with our observation, Lecomte 
et al also suggested that the presence of free-
circulating tumor-associated DNA in plasma is a 
relevant prognostic marker for patients with CRC 
and may be used to identify patients with a high 
risk of recurrence.55 The 2-year overall survival rate 
was 48% (in subjects with free-circulating tumor-
associated DNA detected in their plasma), and 100% 
(in subjects with no detected free-circulating tumor-
associated DNA; p < 0.03). A recent study compared 
the sensitivity and specificity of free circulating 
DNA with that of the more conventional serum 
marker carcinoembryonic antigen (CEA) and showed 
that cell-free circulating DNA, especially when used 
in combination with CEA, represents a potentially 
useful tool for the diagnosis of early stage CRC.56 
Furthermore, the elevated DNA levels in the blood 
of patients with CRC may be a useful tool for de-
tection of this tumor entity and the evaluation of 
therapeutic response.57 Recently, Boni et al dem-
onstrated that circulating free DNA levels in plasma 
of patients with CRC are significantly higher com-
pared with healthy subjects. This suggest a new, 
noninvasive, approach for colon cancer detection 
able to identify high risk individuals for CRC screen-
ing using circulating free DNA as a tumor marker.58
mRNA markers
Because the presence of circulating DNA cannot be 
used to definitely confirm the presence of viable 
CTCs (because of its relatively high stability), re-
searchers have shifted to mRNA because it has a 
shorter half-life once released from tumor cells.59 
mRNA, transcribed from a DNA template, is the in-
termediate between the coding gene and the final 
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product (a protein); at the cellular level, the con-
centration of the respective protein is proportional 
to the mRNA level. As different tumor types typically 
express a different repertoire of protein, the respec-
tive mRNA can be used as a marker for cancer screen-
ing and monitoring. Our previous study exploring 
the molecular detection of CTCs by RT-PCR analy-
sis of the peripheral blood (72 CRC patients and 30 
healthy controls) showed that 69.4% (50/72), 66.7% 
(48/72), 52.8% (38/72), and 72.2% (52/72) of CRC pa-
tients were positive for human telomerase reverse 
transcriptase (hTERT), cyrokeratin-19 (CK-19), cyto-
keratin-20 (CK-20), and CEA mRNA, respectively.60 
The de tec tion of CEA mRNA was significantly cor-
related with depth of tumor invasion (p = 0.012), 
vessel invasion (p = 0.035), UICC stage (p < 0.0001), 
and postoperative metastasis (p < 0.0001); positive 
hTERT mRNA was correlated with UICC stage (p = 
0.037), CK-19 was correlated with depth of tumor 
invasion (p = 0.039) and postoperative metastasis 
(p = 0.017). In addition, multivariate logistic regres-
sion showed that only CEA mRNA was an independent 
and significant predictor of postoperative metas-
tasis (p = 0.006). Our findings suggest that CEA mRNA 
may be a more reliable marker than hTERT, CK-19 
and CK-20 for the detection of circulating cancer 
cells in CRC patients’ peripheral blood. CRC patients 
with positive CEA mRNA in their peripheral blood 
have a significantly higher risk of postoperative 
metastasis. CEA mRNA is not thought to be produced 
by peripheral blood hemopoietic cells, although 
ectopic CEA mRNA expression has been reported in 
bone marrow.61 Ito et al showed that RT-PCR am-
plification of CEA mRNA is an efficient means of 
detecting circulating cancer cells in the peripheral 
blood of CRC patients, and that these disseminated 
tumor cells are associated with high metastatic re-
currence.50 Lledó’s group suggested that detection 
of hTERT mRNA in peripheral blood could be help-
ful for differentiation between healthy and CRC 
patients,62 but no information about its prognostic 
significance for CRC patients is available. In addi-
tion, the controversial roles of cytokeratin mRNA—
considered as molecular markers from previous 
observations—further emphasizes the potential im-
portance of CEA mRNA.63−66 A novel pseudogene il-
lustrates one of the problems that must be addressed 
in validating RT-PCR assays of CK-19 for the detection 
of CTCs.63 No correlation between the detection of 
CK-20 mRNA in the peripheral blood and disease 
progression/survival of CRC patients has been found, 
and CK-20 was thought to have no use as a marker 
for the postoperative surveillance of CRC patients.64−66 
However, Silva et al showed that the detection of 
epithelial tumor mRNAs-CEA and CK-19 by RT-PCR 
(nested PCR) in the plasma of colon cancer patients 
is associated with advanced stages of CTCs.39
Contrary to the above results, Bessa et al sug-
gested that preoperative detection of blood CTCs 
by means of RT-PCR of CEA does not have prognos-
tic significance in patients with CRC.67 It has been 
suggested that a multiple mRNA marker assay can 
provide a more reliable and informative approach 
than a single-marker procedure.68 The combined 
use of negative and positive immunomagnetic beads 
followed by amplification of survivin, CK20 and CEA 
mRNA, by means of Q-RT-PCR is a non-invasive and 
sensitive assay for the improved detection of cir-
culating CRC cells.69 Furthermore, using multiple 
molecular markers of a combined panel in the de-
tection of CTCs is now often used to increase the 
sensitivity of this method.49,68,69 Circulating CRC 
cell positivity rose from 48% (CEA) and 34% (CK-20) 
with one assay from one sample to 74% when both 
assays from three samples were used to identify 
CTCs.49 Conzelmann et al suggested that the con-
comitant use of mRNA and DNA markers is a ra-
tional approach for tracking disseminated tumor 
cells in CRC patients.68 Another study using our 
constructed membrane array-based method simul-
taneously analyzed six mRNA markers and achieved 
a CRC detection rate of 88.2%, with a sensitivity 
of 88.8%, and specificity of 87.8%.70 The results 
again demonstrate that this method—membrane 
array simultaneously analyzing the expression of a 
panel of multiple mRNA markers in the peripheral 
blood of CRC patients—could significantly enhance 
the detection rate of CRC in the clinical context. 
However, the findings reported by Schuster et al 
questions the suitability of compartment peripheral 
blood for the detection of CTCs in CRC patients using 
different mRNA markers.71
Research has shown that serial CEA measure-
ments can detect recurrent CRC with a sensitivity 
of 80%, a specificity of 70%, and a lead time of 
5 months.72 CEA is the most frequent indicator of 
recurrence in asymptomatic patients and is cur-
rently the most cost-effective test for the preclinical 
detection of resectable disease. The identification 
of abnormal pre- and postoperative serum CEA levels 
may be useful in the auxiliary cancer prognosis, 
or in postoperative surveillance of CRC patients.73 
Nevertheless, only limited research has addressed 
the monitoring of recurrence or metastasis in asymp-
tomatic patients—without accompanying serum CEA 
elevation—after curative resection. About half of 
UICC stage I−III CRC patients were found to show 
normal perioperative serum levels.73 We therefore 
analyzed CRC patients with normal perioperative 
serum CEA levels by a panel of molecular markers 
using a constructed membrane array method.74 
This method (for the detection of CTCs) has been 
shown to be complementary to the surveillance of 
CRC patients with normal perioperative serum CEA 
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levels.74 The highly sensitive and high-throughput 
assay has obvious clinical potential for the early 
detection of postoperative relapse, with a lead me-
dian time of 6 months before the measurement of 
abnormal CEA levels.74 The persistent presence of 
postoperative CTCs detected by this method may 
be an adverse prognostic factor, adjuvant to con-
ventional tumor markers in Stage I−III CRC patients 
who have undergone curative resection.75 Iden-
tification of these high-risk patients of persistent 
CTC-positivity is important and could help to select 
patients for adjuvant therapy. For high-risk stage II 
CRC patients, mRNA markers might be taken into 
account as prognostic factors for the considerable 
postoperative relapse rate.76 This would be in ad-
dition to conventional pathological features, such 
as T4 tumors, poorly differentiated histology, tumor 
obstruction or perforation, and less than 12 lymph 
nodes retrieved.77 Consistent with our findings, 
Koch et al also showed the prognostic significance 
of tumor cells detected in the blood samples of 
patients with stage II CRC using CK-20 RT-PCR.78
Another possible explanation of lack of prognos-
tic influence of CTCs in peripheral blood of patients 
with CRC is highlighted by Bessa et al—they detected 
peripheral blood CTCs preoperatively, rather than 
during the operation. As would be expected, a rel-
atively lower incidence (41%) of CRC patients were 
detected with CTC-positivity.67 CK-20 mRNA was not 
always detected in the preoperative blood, even 
in patients in an advanced stage, but it was identi-
fied without fail in intra- and postoperative blood.79 
Circulating mRNA transcripts have been detected 
with greater frequency following CRC surgery, 
prompting some researchers to conclude that sur-
gical manipulation may release tumor cells into the 
circulation.80−82 In fact, preoperative detection of 
micrometastases may reflect either the transient 
shedding of cells, metastatic potential, or residual 
disease; postoperative micrometastases indicate 
minimal residual disease.83
Future Prospects and Challenges
Monitoring the CTCs of peripheral blood post-surgery 
might provide unique information for the clinical 
management of individual CRC patients. By molec-
ular detection, the identification of CRC patients 
at increased risk for recurrence after completion 
of adjuvant chemotherapy is an application of high 
clinical relevance, since these patients might ben-
efit from an additional “second-line” treatment, e.g. 
targeted therapies. However, the false positive and 
negative rates of the membrane-array method in 
predicting postoperative relapse, at least in part, 
might result from CTCs intermittently flowing into 
the bloodstream of the bowel, the heterogeneous 
character of the tumor itself, the sampling timing, 
or carcinoma cells shed into the bloodstream that 
succeed in establishing metastatic disease.83 Using 
multiple blood sampling, a refined normalization 
procedure, or a design more specific to target genes 
might improve the accuracy of the membrane-
array method. Although larger clinical trials will 
be needed to define the exact role in the clinical 
setting, we suggest that early detection of CTCs—
undetectable with current imaging methods or con-
ventional tumor markers—may induce subsequent 
therapeutic strategies and improve outcomes for 
patients with relapse after a curative operation.
In this post-genomic era, tailored chemotherapy 
aims to treat patients with an effective and safe 
drug through the study of drug targets, metaboliz-
ing enzymes, efflux and DNA repair systems at the 
genomic, mRNA, and protein levels. In the past 
decade, significant improvements have been made 
in response rates, progression-free survival (PFS), 
and overall survival (OS) of metastatic CRC (mCRC) 
patients.84 This prominent improvement is mainly 
due to the recent introduction of new combinations 
of standard chemotherapy, including 5-fluorouracil/
folinic acid, irinotecan, oxaliplatin, and new ther-
apeutic agents targeting molecular events involved 
in colorectal carcinogenesis [such as mAbs, against 
the epidermal growth factor receptor (EGFR), or 
mAbs, against vascular endothelial growth factor]. 
Regarding targeted therapies, treatment with ce-
tuximab im proves PFS and OS and preserves the 
quality of life in patients with mCRC that have not 
responded to chemotherapy. The predictive value 
of K-ras mutations in mCRC patients treated with 
cetuximab plus chemotherapy has recently been 
demonstrated. Results have shown that patients 
with tumor K-ras mutations were resistant to 
cetuximab and have shorter PFS and OS times com-
pared with patients without mutations.85,86 Addition-
ally, the National Comprehensive Cancer Network 
Clinical Practice Guidelines in Oncology (Version 3, 
2008) strongly recommends K-ras genotyping of tu-
mor tissue (either primary tumor or metastasis) in all 
patients with mCRC before the treatment with EGFR 
inhibitors.87 Meanwhile, plasma or serum DNA as-
says for the detection of mutations in K-ras may 
provide a feasible method to detect CRC patients 
for somatic mutations frequently found in tumor 
tissues.32,52,53 Furthermore, Di Fiore et al detected 
K-ras mutations in blood using real-time PCR for 
anti-EGFR therapies in mCRC patients. They suggest 
that the collection of blood samples before treat-
ment is probably useful, and there is a clinical inter-
est of these blood tests to detect K-ras mutations.88 
Accordingly, future research—involving molecular 
detection of predictive markers through CTCs in 
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peripheral blood—will provide an innovative and 
alternative tool of clinical implication for individu-
ally targeted chemotherapy. This is in addition to 
standard methods currently available.
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